Top

Published in:

01-09-2012 | Original Paper

Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China

Authors: Xiao Wang, Shuai Wang, Yi-wei Lin, Jian Wu, Hong Chen, Ye-qing Mao, Xiang-yi Zheng, Cheng Zhou, Li-ping Xie

Published in: Medical Oncology | Issue 3/2012

Abstract

As a main effector in the renin-angiotensin system, the angiotensin II plays a critical role in cell proliferation and angiogenesis. The change between angiotensin II and its precursor is conducted by the angiotensin-converting enzyme. The association between angiotensin-converting enzyme insertion/deletion polymorphism and the activity of angiotensin-converting enzyme was testified. Furthermore, previous researches proved the association between angiotensin-converting enzyme activity and the risk of prostate cancer. Therefore, we conducted a case–control study in the Han population of China to elaborate the relation between the angiotensin-converting enzyme insertion/deletion polymorphism and prostate cancer. DNA was extracted from blood samples collected from 189 pathologically diagnosed prostate cancer patients and 290 cancer-free subjects. The angiotensin-converting enzyme insertion/deletion genotype was determined by polymerase chain reaction analysis. Stratified analyses on age (<71 or ≥71), cancer stage (localized or advanced), Gleason score (<7 or ≥7) and PSA level (<20 ng/ml or ≥20 ng/ml) were performed. We found the II genotype (OR = 0.304 95%CI (0.180,0.515), P < 0.001) and I allele (OR = 0.547 95%CI(0.421,0.711), P < 0.001) were associated with a decreased risk of prostate cancer compared with the DD genotype and D allele. The DD genotype was related to patients with aggressive stage of prostate cancer (OR = 2.214 95%CI(1.169, 4.194), P = 0.014) and patients diagnosed of prostate cancer at a relatively early age (OR = 0.513 95%CI(0.272, 0.965), P = 0.037). The results of our experiment supported the hypothesis that the angiotensin-converting enzyme insertion/deletion polymorphism, a potential risk factor in carcinogenesis, played an important role in the Han population of China.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.PubMedCrossRef

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98. doi:10.3322/caac.20066.PubMedCrossRef

Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002;90(2):162–73. doi:10.1046/j.1464-410X.2002.2822.x.PubMedCrossRef

Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet. 2000;67(6):1367–75. doi:10.1086/316916.PubMedCrossRef

Gu F. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J (Engl). 2003;116(9):1391–3.

Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers–results from BPC3. PLoS One. 2011;6(2):e17142. doi:10.1371/journal.pone.0017142.PubMedCrossRef

Belpomme D, Irigaray P, Ossondo M, Vacque D, Martin M. Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe. Int J Oncol. 2009;34(4):1037–44.PubMedCrossRef

Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, et al. Human prostate cancer risk factors. Cancer. 2004;101(10 Suppl):2371–490. doi:10.1002/cncr.20408.PubMedCrossRef

Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT, et al. Epidemiologic determinants of clinically relevant prostate cancer. Int J Cancer. 2000;89(3):259–64. doi:10.1002/1097-0215(20000520)89:3<259::AID-IJC8>3.0.CO;2-F.PubMedCrossRef

10.

Rizos C, Papassava M, Golias C, Charalabopoulos K. Alcohol consumption and prostate cancer: a mini review. Exp Oncol. 2010;32(2):66–70.PubMed

11.

Gard PR. Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet. 2010;1(2):145–57.PubMed

12.

Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179–84. doi:10.1016/S0140-6736(98)03228-0.PubMedCrossRef

13.

Dinh DT, Frauman AG, Johnston CI, Fabiani ME. Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond). 2001;100(5):481–92.CrossRef

14.

Baudin B. Angiotensin II receptor polymorphisms in hypertension Pharmacogenomic considerations. Pharmacogenomics. 2002;3(1):65–73. doi:10.1517/14622416.3.1.65.PubMedCrossRef

15.

George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10(11):745–59. doi:10.1038/nrc2945.PubMedCrossRef

16.

Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267(16):10931–4.PubMed

17.

Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3(2):65–71.PubMed

18.

Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate. 2006;66(8):822–30. doi:10.1002/pros.20407.PubMedCrossRef

19.

Xi B, Zeng T, Liu L, Liang Y, Liu W, Hu Y. et al. Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011. doi:10.1007/s10549-011-1602-3.

20.

Yaren A, Oztop I, Turgut S, Turgut G, Degirmencioglu S, Demirpence M. Angiotensin-converting enzyme gene polymorphism is associated with anemia in non small-cell lung cancer. Exp Biol Med (Maywood). 2008;233(1):32–7. doi:10.3181/0705-RM-141.CrossRef

21.

Loh M, Koh KX, Yeo BH, Song CM, Chia KS, Zhu F, et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer. 2009;45(14):2562–8. doi:10.1016/j.ejca.2009.03.017.PubMedCrossRef

22.

Sierra Diaz E, Sanchez Corona J, Rosales Gomez RC, Gutierrez Rubio SA, Vazquez Camacho JG, Solano Moreno H, et al. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer. J Renin Angiotensin Aldosterone Syst. 2009;10(4):241–6. doi:10.1177/1470320309352800.PubMedCrossRef

23.

Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA. 1988;85(24):9386–90.PubMedCrossRef

24.

Hubert C, Houot AM, Corvol P, Soubrier F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem. 1991;266(23):15377–83.PubMed

25.

Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 1992;20(6):1433.PubMedCrossRef

26.

Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet. 2004;115(2):91–6. doi:10.1007/s00439-004-1136-4.PubMedCrossRef

27.

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343–6. doi:10.1172/JCI114844.PubMedCrossRef

28.

Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51(1):197–205.PubMed

29.

Small W Jr, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF. Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat. 1997;44(3):217–24.PubMedCrossRef

30.

Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med. 1995;210(3):221–6.PubMed

31.

Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer. 1998;77(6):880–3.PubMedCrossRef

32.

Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98(3):671–9. doi:10.1172/JCI118838.PubMedCrossRef

33.

Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastasis. Anticancer Res. 2007;27(2):933–6.PubMed

34.

Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, et al. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol. 2004;202(3):330–5. doi:10.1002/path.1529.PubMedCrossRef

35.

van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam study. Cancer. 2008;112(4):748–57. doi:10.1002/cncr.23215.PubMedCrossRef

36.

Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res. 2003;63(20):6984–7.PubMed

37.

Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003;63(3):573–8.PubMed

38.

Vigano A, Trutschnigg B, Kilgour RD, Hamel N, Hornby L, Lucar E, et al. Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients. Clin Cancer Res. 2009;15(7):2442–7. doi:10.1158/1078-0432.CCR-08-1720.PubMedCrossRef

39.

Rocken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B, et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res. 2005;11(7):2526–30. doi:10.1158/1078-0432.CCR-04-1922.PubMedCrossRef

40.

Ebert MP, Lendeckel U, Westphal S, Dierkes J, Glas J, Folwaczny C, et al. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2987–9. doi:10.1158/1055-9965.EPI-05-0411.PubMedCrossRef

41.

Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58–64.PubMed

42.

Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl. 1993;3(2):120–1.PubMed

43.

Hessels D, Verhaegh GW, Schalken JA, Witjes JA. Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn. 2004;4(4):513–26. doi:10.1586/14737159.4.4.513.PubMedCrossRef

44.

Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst. 2006;98(8):529–34. doi:10.1093/jnci/djj131.PubMedCrossRef

45.

Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, et al. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1871–8. doi:10.1158/1055-9965.EPI-10-0216.PubMedCrossRef

46.

McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62(12):3369–72.PubMed

47.

Bai Y, Yu Y, Yu B, Ge J, Ji J, Lu H, et al. Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet. 2009;10:125. doi:10.1186/1471-2350-10-125.PubMedCrossRef

48.

Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, et al. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther. 2009;8(12):3255–65. doi:10.1158/1535-7163.MCT-09-0237.PubMedCrossRef

49.

Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate. 2007;67(9):924–32. doi:10.1002/pros.20571.PubMedCrossRef

50.

Hoshino K, Ishiguro H, Teranishi J, Yoshida S, Umemura S, Kubota Y, et al. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate. 2011;71(9):964–75. doi:10.1002/pros.21312.PubMedCrossRef

51.

Attoub S, Gaben AM, Al-Salam S, Al Sultan MA, John A, Nicholls MG, et al. Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci. 2008;1138:65–72. doi:10.1196/annals.1414.011.PubMedCrossRef

52.

Hamdi HK, Castellon R. A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. Biochem Biophys Res Commun. 2004;318(1):187–91. doi:10.1016/j.bbrc.2004.04.004.PubMedCrossRef

53.

Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol. 2002;20(6):1227–31.PubMed

54.

Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002;23(6):348–56. doi:10.1159/000069792.PubMedCrossRef

Title: Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China
Authors: Xiao Wang
Shuai Wang
Yi-wei Lin
Jian Wu
Hong Chen
Ye-qing Mao
Xiang-yi Zheng
Cheng Zhou
Li-ping Xie
Publication date: 01-09-2012
Publisher: Springer US
Published in: Medical Oncology / Issue 3/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-011-0051-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

An essential role of PDCD4 in progression and malignant proliferation of gastrointestinal stromal tumors

The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis

Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival

Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome

Neoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancer

Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage